Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin Absorption in Subclinical Lipohypertrophy
NCT03229850Withdrawn
- Start
- Feb 2021
- Primary completion
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of insulin lispro in type 2 diabetes mellitus (T2DM) (2 arms). Primary endpoint: Insulin Levels at 2 months. Planned start Feb 2021; status: withdrawn.
02
Drugs
insulin lispro
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03229850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03229850.